Skip to main content

Advertisement

SpringerLink
Log in

Medical therapies for pulmonary arterial hypertension

  • Published:
Heart Failure Reviews Aims and scope Submit manuscript

Abstract

Pulmonary Arterial hypertension (PAH) is a chronic and progressive disease characterized by an increase in pulmonary vascular resistance due to severe remodeling of the small pulmonary arteries. In PAH, the endothelial cells fail to maintain their homeostatic balance, with the consequent impaired production of vasodilators and over-expression of vasoconstrictors and proliferators. Current treatment of PAH is based on the discovery of three main pathways of endothelial dysfunction (prostacyclin, nitric oxide and endothelin-1), and includes drugs such as prostacyclin analogs, phosphodiesterase-5 inhibitors and endothelin receptor antagonists (ERAs). Recently approved drugs that act through these classic pathways include riociguat (cyclic GMP stimulator) and macitentan (a tissue specific dual ERA). However, several new drugs and new pathways are under study. New targeted therapies include tyrosine kinase inhibitors, Rho kinase inhibitors and serotonin receptor blockers. There are now ten drugs approved for the treatment of PAH that, alone or in combination, have changed the natural history of this disease. The new drugs will allow us to further modified the patients’ life expectancy and move towards a cure.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Galiè N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barberá JA et al (2009) Guidelines for the diagnosis and treatment of pulmonary hypertension. The taskforce for the diagnosis and treatment of pulmonary hypertension of the European society of cardiology, the European respiratory society, endorsed by the international society of heart and lung transplantation. Eur Heart J 30:2493–2537

    Article  PubMed  Google Scholar 

  2. Humbert M, Sitbon O, Simonneau G et al (2004) Treatment of pulmonary arterial hypertension. N Eng J Med 2004(351):1425–1436

    Article  Google Scholar 

  3. Tuder RM, Archer SL, Dorfmüller P, Erzurum SC, Guignabert C, Michelakis E et al (2013) Relevant issues in the pathology and pathobiology of pulmonary hypertension. J Am Coll Cardiol 6:D4–D12

    Article  Google Scholar 

  4. Galiè N, Corris PA, Frost A, Girgis RE, Granton J, Cheng Jing Z et al (2013) Updated treatment algorithm of pulmonary arterial hypertension. J Am Coll Cardiol 62:D60–D72

    Article  PubMed  Google Scholar 

  5. Fortin TA, Tapson VF. (2004) Intravenous prostacyclin for pulmonary arterial hypertension. In: Peacock AJ, Rubin LJ (Eds.), Pulmonary circulation. Diseases and treatment, Arnold:London

  6. Barst RJ, Rubin LJ, Long WA et al (1996) A comparison of continues intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 334:296–302

    Article  CAS  PubMed  Google Scholar 

  7. Sitbon O, MD; Humbert M, M; Nunes HMD et al. (2002) Long-term intravenous epoprostenol infusión in primary pulmonary hypertension: prognostic factors and survival. JACC Pulmonary Hypertension vol. 40, No. 4

  8. McLaughlin VV, Shillington A, Rich S et al (2002) Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 106:1477–1482

    Article  CAS  PubMed  Google Scholar 

  9. Rich S, McLaughlin VV et al (1999) The effects of chronic prostacyclin therapy on cardiac output in primary pulmonary hypertension. J Am Coll Cardiol 34:1184–1187

    Article  CAS  PubMed  Google Scholar 

  10. Lambert O, Bandilla D, Iyer R, Witchey-Lakshmanan L, Palepu N (2012) Stability and microbiological properties of a new formulation of epoprostenol sodium when reconstituted and diluted. Drug Des Dev Ther 6:61–70

    Article  CAS  Google Scholar 

  11. Montani D, Chaumais MC, Guignabert C, Gunther S, Girerd B, Jaïs X et al (2013) Targeted therapies in pulmonary arterial hypertension. Pharmacol Ther 141:172–191

    Article  PubMed  Google Scholar 

  12. Sitbon O, Delcroix M, Bergot E, Boonstra AB, Granton J, Langleben D et al (2014) EPITOME-2: an open-label study assessing the transition to a new formulation of intravenous epoprostenol in patients with pulmonary arterial hypertension. Am Heart J 167:210–217

    Article  CAS  PubMed  Google Scholar 

  13. Olschewski H, Simonneau G, Galie N, Higembottan T, Naeije R, Rubin LJ et al (2002) Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 347:322–329

    Article  CAS  PubMed  Google Scholar 

  14. Hoeper MM, Schwarze M, Ehlerding S, Adler-Schuermeyer A, Spiekerkoetter E, Niedermeyer J et al (2000) Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. N Engl J Med 342:1866–1870

    Article  CAS  PubMed  Google Scholar 

  15. Simonneau G, Barst RJ, Galie N, Naeije R, Rich S, Bourge RC et al (2002) Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 165:800–804

    Article  PubMed  Google Scholar 

  16. Tapson VF, Gomberg-Maitland M, McLaughlin VV, Benza RL, Widlitz AC, Krichman A, Barst RJ (2006) Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open-label, 12-week trial. Chest 129:683–688

    Article  CAS  PubMed  Google Scholar 

  17. McLaughlin VV, Benza RL, Rubin LJ, Channick RN, Voswinckel R, Tapson VF et al (2010) Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. J Am Coll Cardiol 4(55):1915–1922

    Article  Google Scholar 

  18. Jing ZC, Parikh K, Pulido T, Jerjes-Sánchez C, White J, Robblee A et al (2013) Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial. Circulation 127:624–633

    Article  CAS  PubMed  Google Scholar 

  19. Tapson VF, Torres F, Kermeen F, Keogh AM, Allen RP, Frantz RP et al (2012) Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study). A randomized controlled trial. Chest 142:1383–1390

    Article  CAS  PubMed  Google Scholar 

  20. Tapson VF, Jing ZS, Xu KF, Pan L, Feldman J, Kiely DG et al (2013) Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (The FREEDOM-C2 study). A randomized controlled trial. Chest 144:952–958

    Article  CAS  PubMed  Google Scholar 

  21. Galiè N, Humbert M, Vachiéry JL, Vizza CD, Kneussl M, Manes A et al (2002) Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 39:1496–1502

    Article  PubMed  Google Scholar 

  22. Barst RJ, McGoon M, McLaughlin V, Tapson V, Rich S, Rubin L et al. (2003) Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol 41:2119–25. Erratum in: J Am Coll Cardiol 42:591

  23. Yanagisawa M, Kurihara K, Kimura S, Tomobe Y, Kobayashi M, Mitsuie Y et al (1988) A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332:411–415

    Article  CAS  PubMed  Google Scholar 

  24. Markewitz BA, Farrukh IS, Chen Y, Li Y, Michael JR (2001) Regulation of endothelin-1 synthesis in human pulmonary arterial smooth muscle cells. Effects of transforming growth factor- and hypoxia. Cardiovasc Res 49:200–206

    Article  CAS  PubMed  Google Scholar 

  25. Shi-Wen X, Chen Y, Denton CP, Eastwood M, Renzoni EA, Bou-Gharios G et al (2004) Endothelin-1 promotes myofibroblast induction through the ETA receptor via a rac/phosphoinositide 3-kinase/Akt-dependent pathway and is essential for the enhanced contractile phenotype of fibrotic fibroblasts. Mol Biol Cell 15:2707–2719

    Article  PubMed  PubMed Central  Google Scholar 

  26. Channick RN, Simonneau G, Sitbon O, Robbins IM et al (2001) Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 358:1119–1123

    Article  CAS  PubMed  Google Scholar 

  27. Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A et al. (2002) Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 346:896–903. Erratum in N Engl J Med 2002;346:1258

  28. Galiè N, Hinderliter AL, Torbicki A, Fourme T, Simonneau G, Pulido T et al (2003) Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and Doppler measures in patients with pulmonary arterial hypertension. J Am Coll Cardiol 41:1380–1386

    Article  PubMed  Google Scholar 

  29. McLaughlin VV, Sitbon O, Badesch DB, Barst RJ, Black C, Galiè N et al (2005) Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J 25:244–249

    Article  CAS  PubMed  Google Scholar 

  30. Galiè N, Badesch D, Oudiz R, Simonneau G, McGoon MD, Keogh AM et al (2005) Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol 46:529–535

    Article  PubMed  Google Scholar 

  31. Galiè N, Olschewski H, Oudiz RJ, Torres F, Frost A, Ghofrani HA et al (2008) Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicentre, efficacy (ARIES) study 1 and 2. Circulation 117:3010–3019

    Article  PubMed  Google Scholar 

  32. Iglarz M, Binkert C, Morrison K, Fischli W, Gatfield J, Treiber A et al (2008) Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist. J Pharmacol Exp Ther 327:736–745

    Article  CAS  PubMed  Google Scholar 

  33. Sidharta PN, van Giersbergen PL, Dingemanse J (2013) Safety, tolerability, pharmacokinetics, and pharmacodynamics of macitentan, an endothelin receptor antagonist, in an ascending multiple-dose study in healthy subjects. J Clin Pharmacol 53:1131–1138

    CAS  PubMed  Google Scholar 

  34. Pulido T, Adzerikho I, Channick RN, Delcroix M, Galiè N, Ghofrani HA et al (2013) Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med 369:809–818

    Article  CAS  PubMed  Google Scholar 

  35. Rybalkin SD, Yan C, Bornfeldt KE, Beavo JA (2003) Cyclic GMP phosphodiesterases and regulation of smooth muscle function. Circ Res 93:280–291

    Article  CAS  PubMed  Google Scholar 

  36. Galie N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch DB et al (2005) Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 353:2148–2157

    Article  CAS  PubMed  Google Scholar 

  37. Rubin LJ, Badesch DB, Fleming TR, Galiè N, Simonneau G, Ghofrani HA et al (2011) Long-term treatment with sildenafil citrate in pulmonary arterial hypertension: the SUPER-2 study. Chest 140:1274–1283

    Article  CAS  PubMed  Google Scholar 

  38. Barst RJ, Ivy DD, Gaitan G, Szatmari A et al (2012) A randomized, double-blind, placebo-controlled, dose ranging study of oral sildenafil citrate in treatment-naïve children with pulmonary hypertension. Circulation 125:324–334

    Article  CAS  PubMed  Google Scholar 

  39. Barst RJ, Beghetti M, Pulido T et al (2014) Long term survival with oral sildenafiin treatment-naïve pediatric pulmonary hypertension. Circulation 129:1914–1923

    Article  CAS  PubMed  Google Scholar 

  40. Galiè N, Brundage BH, Ghofrani HA, Oudiz RJ, Simonneau G, Safdar Z et al (2009) Tadalafil therapy for pulmonary arterial hypertension. Circulation 119:2894–2903

    Article  PubMed  Google Scholar 

  41. Stasch JP, Evgenov OV (2009) Soluble guanylate cyclase stimulators in pulmonary hypertension. Handb Exp Pharmacol 218:279–313

    Article  Google Scholar 

  42. Grimminger F, Weimann G, Frey R, Voswinckel R, Thamm M, Bölkow D et al (2009) First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension. Eur Respir J 33:785–792

    Article  CAS  PubMed  Google Scholar 

  43. Ghofrani HA, Hoeper MM, Halank M, Meyer FJ, Staehler G, Behr J et al (2010) Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study. Eur Respir J 36:792–799

    Article  CAS  PubMed  Google Scholar 

  44. Ghofrani HA, Galiè N, Grimminger F, Grünig E, Humbert M, Jing ZC et al (2013) Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med 369:330–340

    Article  CAS  PubMed  Google Scholar 

  45. Rubin LJ, Galie N, Grimminger F et al. (2015) Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2). Eur Res J 45:1303–1313

    Article  CAS  Google Scholar 

  46. McLaughlin VV, Gaine SP, Howard LS, Leuchte HH, Mathier MA, Mehta S et al (2013) Treatment goals of pulmonary hypertension. J Am Coll Cardiol 62:D73–D81

    Article  PubMed  Google Scholar 

  47. Galiè N, Manes A (2013) New treatment strategies for pulmonary arterial hypertension. Hopes or hypes? J Am Coll Cardiol 12:1101–1102

    Article  Google Scholar 

  48. Galiè N, Palazzini M, Manes A (2010) Pulmonary arterial hypertension: from the kingdom of the near-dead to multiple clinical trial meta-analyses. Eur Heart J 31:2080–2086

    Article  PubMed  PubMed Central  Google Scholar 

  49. Galié N, Barbera J, Frost A et al (2015) Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension. N Engl J Med 373:834–844

    Article  PubMed  Google Scholar 

  50. Galie N, (co-chair) Humbert M (co-chair), (2015) ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. The joint task force for the diagnosis and treatment of pulmonary hypertension of the European society of cardiology (ESC) and the European respiratory society (ERS). Eur Respir J. 46(6):1855–6

  51. Simonneau G, Torbicki A, Hoeper MM, Delcroix M, Karlokai K, Galiè N et al (2012) Selexipag: an oral selective prostacyclin selective receptor agonist for the treatment of pulmonary arterial hypertension. Eur Respir J 40:874–880

    Article  CAS  PubMed  Google Scholar 

  52. Montani D, Bergot E, Günther S (2012) Pulmonary Arterial Hypertension in patients treated by Dasatinib. Circulation 125:2128–2137

    Article  CAS  PubMed  Google Scholar 

  53. Sitbon O, Morrell NW (2012) Pathways in pulmonary arterial hypertension: the future is here. Eur Respir Rev 21:321–327

    Article  PubMed  Google Scholar 

  54. Girgis RE (2010) Emerging drugsfor pulmonary hypertension. Expert Opin Emerg Drugs 15:71–85

    Article  CAS  PubMed  Google Scholar 

  55. Galiè N, Ghofrani HA (2013) New horizons in pulmonary arterial hypertension therapies. Eur Respir Rev 22:503–514

    Article  PubMed  Google Scholar 

  56. Kuwano K, Hashino A, Asaki T, Hamamoto T, Yamada T, Okubo K, Kuwabara K (2007) 2-[4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy]-N-(methylsulfonyl)acetamide (NS-304), an orally available and long-acting prostacyclin receptor agonist prodrug. J Pharmacol Exp Ther 322:1181–1188

    Article  CAS  PubMed  Google Scholar 

  57. Sitbon O, Channick R, Chin KM, Frey A, et al (2015) Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med 373:2522–2533

    Article  Google Scholar 

  58. Schermuly RT, Dony E, Ghofrani HA, Pullamsetti S, Savai R, Roth M et al (2005) Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest 115:2811–2821

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Ghofrani HA, Morrell NW, Hoeper MM, Olschewski H, Peacock AJ, Barst RJ et al (2010) Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy. Am J Respir Crit Care Med 182:1171–1177

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Hoeper M, Bogaard HJ, Condliffe R et al (2013) Definition and diagnosis of pulmonary hypertension. Turk Kardiyol Dern Ars

  61. Gomberg-Maitland M, Maitland ML, Barst RJ, Sugeng L, Coslet S, Perrino TJ et al (2010) A dosing/cross-development study of the multikinase inhibitor sorafenib in patients with pulmonary arterial hypertension. J Clin Pharmacol Ther 87:303–310

    Article  CAS  Google Scholar 

  62. Atallah E, Durand JB, Kantarjian H, Cortes J (2007) Congestive heart failure is a rare event in patients receiving imatinib therapy. Blood 110:1233–1237

    Article  CAS  PubMed  Google Scholar 

  63. Mouchaers KT, Schalij I, de Boer MA, Postmus PE, van Hinsbergh VW, van Nieuw Amerongen GP et al (2010) Fasudil reduces monocrotaline-induced pulmonary arterial hypertension: comparison with bosentan and sildenafil. Eur Respir J 36:800–807

    Article  CAS  PubMed  Google Scholar 

  64. Fukumoto Y, Matoba T, Ito A, Tanaka H, Kishi T, Hayashidani S et al (2005) Acute vasodilator effects of a Rho-kinase inhibitor, fasudil, in patients with severe pulmonary hypertension. Heart 91:391–392

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. Fujita H, Fukumoto Y, Saji K, Sugimura K, Demachi J, Nawata J, Shimokawa H (2010) Acute vasodilator effects of inhaled fasudil, a specific Rho-kinase inhibitor, in patients with pulmonary arterial hypertension. Heart Vessels 25:144–149

    Article  PubMed  Google Scholar 

  66. Pankey EA, Byun RJ, Smith WB 2nd, Bhartiya M, Bueno FR, Badejo AM et al (2012) The Rho kinase inhibitor azaindole-1 has long-acting vasodilator activity in the pulmonary vascular bed of the intact chest rat. Can J Physiol Pharmacol 90:825–835

    Article  CAS  PubMed  Google Scholar 

  67. McLean DL, Sillar KT (2004) Divergent actions of serotonin receptor activation during fictive swimming in frog embryos. J Comp Physiol A Neuroethol Sens Neural Behav Physiol 190:391–402 Epub 2004 Feb 26

    Article  CAS  PubMed  Google Scholar 

  68. Guignabert C, Raffestin B, Benferhat R, Raoul W et al (2005) Serotonin transporter inhibition prevents and reverses monocrotaline-induced pulmonary hypertension in rats. Circulation 111:2812–2819

    Article  CAS  PubMed  Google Scholar 

  69. Dumitrascu R, Kulcke C, Königshoff M, Kouri F, Yang X, Morrell N et al (2011) Terguride ameliorates monocrotaline-induced pulmonary hypertension in rats. Eur Respir J 37:1104–1118

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cardiopulmonary Department, Ignacio Chavez National Heart Institute, 1 Juan Badiano, 4th Floor, 14080, Mexico City, Mexico

    Tomas Pulido, Nayeli Zayas, Maitane Alonso de Mendieta, Karen Plascencia & Jennifer Escobar

Authors
  1. Tomas Pulido
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nayeli Zayas
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Maitane Alonso de Mendieta
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Karen Plascencia
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jennifer Escobar
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tomas Pulido.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Pulido, T., Zayas, N., de Mendieta, M.A. et al. Medical therapies for pulmonary arterial hypertension. Heart Fail Rev 21, 273–283 (2016). https://doi.org/10.1007/s10741-016-9527-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10741-016-9527-x

Keywords

Search

Navigation